Classification and treatment of radiation maculopathy.
Horgan, Noel Shields, Carol L Mashayekhi, Arman Shields, Jerry A
Horgan, Noel
Shields, Carol L
Mashayekhi, Arman
Shields, Jerry A
Advisors
Editors
Other Contributors
Date
2012-02-01T10:40:14Z
Date Submitted
Keywords
Other Subjects
Subject Mesh
Fluorescein Angiography
Humans
Radiation Injuries/*classification/etiology/*therapy
Radiotherapy/*adverse effects
Retina/*radiation effects
Retinal Diseases/*classification/etiology/*therapy
Tomography, Optical Coherence
Uveal Neoplasms/radiotherapy
Humans
Radiation Injuries/*classification/etiology/*therapy
Radiotherapy/*adverse effects
Retina/*radiation effects
Retinal Diseases/*classification/etiology/*therapy
Tomography, Optical Coherence
Uveal Neoplasms/radiotherapy
Planned Date
Start Date
Collaborators
Principal Investigators
Alternative Titles
Publisher
Abstract
PURPOSE OF REVIEW: Radiation maculopathy is a sight-limiting consequence of radiotherapy in the management of uveal melanoma and other intraocular tumors. In this review, we consider clinical, fluorescein angiographic and optical coherence tomographic findings, propose a classification for radiation maculopathy and discuss the management of this condition. RECENT FINDINGS: Radiation macular edema (RME) can be classified by optical coherence tomography into noncystoid or cystoid edema, with foveolar or extrafoveolar involvement. Optical coherence tomographic grading of RME has been found to correlate with visual acuity. Focal argon laser might have some limited benefit in the treatment of RME. Intravitreal triamcinolone and intravitreal antivascular endothelial growth factor agents can be of short-term benefit in the treatment of RME. In a randomized controlled trial, periocular triamcinolone significantly reduced rates of RME and vision loss up to 18 months following plaque radiotherapy for uveal melanoma. SUMMARY: Currently, there is no proven treatment for established RME, though periocular triamcinolone has been shown to have a preventive benefit. An accepted classification system for radiation maculopathy would be of benefit in planning and comparing future treatment trials.
Language
eng
ISSN
1531-7021 (Electronic)
1040-8738 (Linking)
1040-8738 (Linking)
eISSN
ISBN
DOI
10.1097/ICU.0b013e3283386687
PMID
20393294